Switching From Omalizumab to OMLYCLO in Asthma or Hives
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study follows patients with severe asthma or chronic hives who are already on omalizumab (Xolair) and are switching to a very similar, lower-cost biosimilar called OMLYCLO. It aims to see if the switch works well in real-world practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have severe asthma or chronic spontaneous urticaria (long-lasting hives)
- You have been treated with the original omalizumab (Xolair) for at least 6 months
- Your disease has been stable for the last 3 months (e.g., no asthma attacks needing steroids, or hive scores well-controlled)
- Your doctor has decided to switch you to OMLYCLO (a biosimilar version of omalizumab) as part of your regular care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how diet and oxidative stress (a type of cell damage) affect the severity of chronic hives and how well patients respond to the medication omalizumab (Xolair). It may help find ways to improve treatment by understanding these factors.
This study tests whether a bacterial lysate medicine (OM-85) combined with allergy medication can better control chronic hives in people whose regular allergy pills aren't working well enough. You'll be observed over time to see if this combination is safe and effective.
This study tests a new oral medication (TLL-018) for people with chronic spontaneous urticaria (hives that last more than 6 weeks) who still have symptoms despite taking antihistamines. The goal is to see if the drug can reduce itching and hives better than placebo.
This study tests whether a new drug called MG-K10 can help people with chronic hives (itchy welts) that haven't improved with standard allergy medications. MG-K10 works differently than regular allergy pills, targeting a specific immune pathway that causes hives.
This study tests a new drug, TLL-018, for people with moderate-to-severe chronic hives (CSU) that don't respond well to standard antihistamines. The goal is to see if it works quickly to reduce itching and hives.
This Phase 4 study looks at whether extending the time between omalizumab injections can still control chronic spontaneous hives (CSU). It may help some people need fewer injections while keeping symptoms under control.
Hear when a new Allergic Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.